Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases.The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem cell [...]

Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury.A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement from [...]

Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack.The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement from [...]

A new common stock purchase agreement with Aspire Capital Fund LLC will give Cleveland biopharmaceutical company Athersys (NASDAQ:ATHX) up to $20 million in investment dollars.Chicago-based Aspire has committed to purchasing up to $20 million in Athersys common stock over the next two years, with Athersys controlling the timing and the amount of the purchases to [...]

Athersys (Nasdaq:ATHX) has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS.Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will commit up to $640,000 to fund animal studies of Athersys’ MultiStem in treating MS, a disease that attacks the central [...]

Stem cell developer Athersys (NASDAQ:ATHX) has taken the next of many steps toward commercializing its MultiStem therapy for stroke, the most promising application for the therapy.The Cleveland-based company detailed its plans for a phase 2 ischemic stroke clinical trial that’s estimated to involve about 140 patients, according to ClinicalTrials.gov, a website maintained by the National [...]

Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year.Moving ahead with its stroke therapy is key for Athersys because that application represents its biggest market. CEO Gil Van Bokkelen pegged the potential stroke market at [...]

As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NASDAQ:ATHX) is particularly vulnerable to big drops in its share price.That’s because Athersys’s primary method for raising cash is through direct offerings of its shares, such as an offering that raised $13 million for the [...]

Athersys (NASDAQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients.The positive results from a one-year followup on the trial will pave the way for Cleveland-based Athersys to begin a phase 2 trial on heart attack patients later this year, [...]

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive interim results from a phase 1 clinical trial in patients with leukemia or similar blood cancers.The trial showed that the company’s MultiStem technology was well tolerated at all dose levels and also suggested that the technology may reduce the incidence of severe graft-versus-host disease, according [...]